• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Recent Advances in the Study of 4-di-n-propylamino-1-butanol (CAS: 51599-79-2): A Comprehensive Research Brief

4-di-n-propylamino-1-butanol (CAS: 51599-79-2) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This tertiary amino alcohol derivative has shown promising pharmacological properties, particularly in the context of neurotransmitter modulation and receptor binding studies. Recent literature highlights its structural similarity to known bioactive molecules, making it a valuable scaffold for drug development.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's potential as a dopamine receptor modulator. Researchers employed molecular docking simulations and in vitro binding assays to demonstrate 4-di-n-propylamino-1-butanol's selective affinity for D2-like dopamine receptor subtypes. The study revealed an unexpected allosteric binding mechanism, with the propylamino groups playing a crucial role in receptor interaction (IC50 = 3.2 μM).

In the field of synthetic chemistry, advances have been made in the stereoselective synthesis of 4-di-n-propylamino-1-butanol. A team from ETH Zurich developed a novel catalytic asymmetric hydrogenation method that achieves >99% enantiomeric excess (Angewandte Chemie, 2024). This breakthrough addresses previous challenges in obtaining optically pure forms of the compound, which is critical for pharmacological applications where stereochemistry significantly impacts biological activity.

Pharmacokinetic studies published in Drug Metabolism and Disposition (2023) have provided new insights into the compound's metabolic fate. Using LC-MS/MS analysis, researchers identified three major metabolites formed through N-dealkylation and hydroxylation pathways. Notably, the terminal hydroxyl group was found to undergo rapid glucuronidation, suggesting potential for prodrug development to enhance bioavailability.

Recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2024) have established preliminary safety profiles for 4-di-n-propylamino-1-butanol. Acute toxicity studies in rodent models showed an LD50 of 450 mg/kg (oral), while 28-day repeated dose studies revealed no significant organ toxicity at therapeutic dose ranges. These findings support further investigation of the compound for potential clinical applications.

Emerging applications in radiopharmaceuticals have been reported, with 11C-labeled derivatives of 4-di-n-propylamino-1-butanol showing promise as PET tracers for neurological imaging. A multicenter study demonstrated excellent blood-brain barrier penetration and specific binding in primate models (Journal of Nuclear Medicine, 2024), opening new avenues for diagnostic applications in neurodegenerative disorders.

The compound's physicochemical properties have been systematically characterized in recent work (Journal of Pharmaceutical Sciences, 2023). Key findings include a logP of 2.1 ± 0.2, pKa of 9.4, and excellent solubility in common pharmaceutical solvents. These properties make it particularly suitable for formulation development, with several patents filed in 2024 for novel delivery systems incorporating 4-di-n-propylamino-1-butanol.

Ongoing clinical trials (Phase I) are investigating derivatives of 4-di-n-propylamino-1-butanol as potential treatments for movement disorders. Preliminary results presented at the 2024 American Academy of Neurology meeting showed favorable safety profiles and dose-dependent pharmacological effects, though efficacy data remain pending. These developments position the compound as an important lead in CNS drug discovery pipelines.

• 4672-11-1(4-(1-Piperidinyl)-1-butanol)
• 13330-96-6(4-Dimethylamino-1-butanol)
• 93264-47-2(4-(Pyrrolidin-1-yl)butan-1-ol)
• 2683-57-0(5-(Diethylamino)pentan-1-ol)
• 2050-51-3(3-(Dibutylamino)-1-propanol)
• 29823-87-8(8-Dimethylamino-1-octanol)
• 27384-58-3(5-(dimethylamino)pentan-1-ol)
• 2937-83-9(1-Piperidinepentanol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)